


Haematological malignancies in focus

SureSeq[™] NGS products



An expanding portfolio of NGS panels for research into haematological malignancies, as well as library preparation kits and NGS analysis software for the accurate detection of a wide range of genetic aberrations.

SureSeq™ NGS panels have been designed in collaboration with recognised cancer experts to ensure the most relevant gene content. By leveraging expertise in hybridisation-based enrichment, SureSeq™ offers unparalleled coverage completeness and uniformity in key biomarkers such as NPM1, CEBPA and FLT3-ITDs.

Enhanced detection of complex variants SNVs, Indels, ITDs,

SNVs, Indels, ITDs, PTDs, CNVs, LOH and translocations. VAF down to a possible 0.01%.


+ DODOO + DODOO - SureSeq

Seamless customisation

Choose from over 1000 pre-optimised genomic targets to tailor your SureSeq myPanel.

Universal NGS Workflow Solution V2

A simplified reagent system optimised for high-performance and reduced hands-on time.



Interpret NGS Analysis Software

Complimentary unlimited use to our highly configurable and powerful software. Locally installed or on the cloud.

Track your myeloid sample from characterisation to monitoring

SureSeq™ Core MPN (+ BRC-ABL) Panel

- Core content: CALR, JAK2, MPL. Customise by adding BCR::ABL translocation
- 1-day sample-to-sequencer: streamlined library preparation and 30-minute hybridisation



SureSeq[™] Myeloid Plus Panel

Mid-size content: detect SNVs and indels in 49 genes implicated in myeloid malignancies down to 2.5% VAF (including robust detection of *FLT3*-ITDs and *KMT2A*-PTDs), together with 44 SNPs as ID markers and 4 sex chromosome genes

SureSeq[™] Pan-Myeloid Panel

Comprehensive content: confidently detect low-frequency SNVs and indels down to 1% VAF in 70 genes implicated in myeloid malignancies, including robust detection of *FLT3*-ITDs and *KMT2A*-PTDs

SureSeq[™] Myeloid Fusion Panel

- RNA-based, following the latest WHO guidelines: detect 30 common myeloid fusions
- Partner gene-agnostic panel: discover novel fusion partners in a single cost-efficient assay, including KMT2A and MECOM



SureSeq[™] Myeloid MRD Panel

- **Ultra-low sensitivity:** flexible sensitivity workflow designed to detect low-frequency variants down to a possible 0.01% VAF with confidence in key biomarkers such as *NPM1*, *CEBPA* and *FLT3*-ITDs
- **Guideline-driven gene content:** detect SNVs and indels in 45 hotspot exons across 13 genes associated with accurate MRD detection in AML samples including MDS and MPN implicated genes



Gain deeper insights into CLL progression

SureSeq™ CLL + CNV V3 Panel

- Latest evidence-based content: extended gene coverage for TP53, BTK and PLCG2, plus inclusion of BCL2 and NRAS
- Outstanding uniformity and depth of coverage: low frequency SNVs and indels down to 1–2.5% VAF in 16 genes
- Superior somatic CNV calling: in the 5 most common regions down to 20% tumour content



The complete solution

Universal NGS Workflow Solution V2

- Streamlined workflow: enzymatic fragmentation, end repair and A-tailing in one-step. Use the same workflow across all our panels
- Unique Dual Index (UDI)/Unique Molecular Index (UMI): increasing multiplexing efficiency and confidence
- Complete solution: simplified system including all necessary reagents, without the need for expensive supporting hardware



Interpret NGS Analysis Software

- Detection of a wide range of aberrations: reliably call variants ranging from low-frequency SNVs and indels to large structural deletions including CNVs and translocations, including longitudinal monitoring
- Extensive customisation and filtering options: easily customise variant and batch reports and database links to meet your analytical criteria
- On-cloud or on-prem: flexible options of software usage with local installation or on cloud



SureSeq™: For Research Use Only; Not for Use in Diagnostic Procedures.